Pursuant to section 23(1) of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine which was referred to the Minister of Health under the provisions of section 24(5) of the Act and set out in the Schedule hereto:
Schedule
Product: | Brukinsa |
Active Ingredient: | Zanubrutinib 80mg |
Dosage Form: | Capsule |
New Zealand Sponsor: | BeiGene NZ Unlimited |
Manufacturer: | Catalent CTS Inc, Missouri, United States of America |
Provisional consent is granted until 8 June 2025. |
|
This consent is given subject to the following conditions.
|
Dated this 23rd day of January 2024.
DEREK FITZGERALD, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).